The researchers found that 72 percent of board or governing council members at 10 of the top medical societies are involved in substantial financial relationships with drugmakers and devicemakers.
The study comes amid public concern over how the financial interests of medical societies affect clinical research, treatment regulation and physician education.
“These extensive ties between doctors and industry can undermine the integrity of research, education and practice — and threaten public trust in medicine,” Raymond Moynihan, PhD, one of the study’s authors, told STAT.
More articles on pharmacy:
WHO suspends hydroxychloroquine trial over safety concerns
Drugmakers worried about Washington’s push to bring drug manufacturing back to US
Anti-anxiety drug prescriptions rise, spur addiction, abuse concerns
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
